Characterization of iRGD-Ligand Modified Arginine-Histidine-Rich Peptides for Nucleic Acid Therapeutics Delivery to αvβ3 Integrin-Expressing Cancer Cells.

Pharmaceuticals (Basel) · 2020 · PMC7601072 · PMID 33050526

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

only marginally significantp < 0.05actually significant

However, the differences between ligand-modified and unmodified DNA-complexes were only marginally significant (0.03 < p < 0.05).

also in 5,085 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.